As global markets navigate a landscape marked by mixed performances and cautious economic outlooks, investors are increasingly exploring diverse opportunities. Penny stocks, often seen as remnants of past market eras, continue to offer intriguing prospects due to their affordability and potential for growth. By focusing on companies with strong financial foundations, these investments can reveal hidden value and unexpected returns in the ever-evolving Asian market.
Top 10 Penny Stocks In Asia
| Name | Share Price | Market Cap | Rewards & Risks |
| JBM (Healthcare) (SEHK:2161) | HK$2.99 | HK$2.43B | ✅ 3 ⚠️ 1 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.48 | HK$915.41M | ✅ 4 ⚠️ 1 View Analysis > |
| Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC) | THB2.72 | THB1.14B | ✅ 3 ⚠️ 2 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.51 | HK$2.08B | ✅ 4 ⚠️ 1 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD1.04 | SGD421.5M | ✅ 4 ⚠️ 2 View Analysis > |
| T.A.C. Consumer (SET:TACC) | THB4.92 | THB2.95B | ✅ 3 ⚠️ 3 View Analysis > |
| Atlantic Navigation Holdings (Singapore) (Catalist:5UL) | SGD0.097 | SGD50.78M | ✅ 2 ⚠️ 4 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD3.26 | SGD12.83B | ✅ 5 ⚠️ 1 View Analysis > |
| Anton Oilfield Services Group (SEHK:3337) | HK$0.96 | HK$2.57B | ✅ 3 ⚠️ 2 View Analysis > |
| Livestock Improvement (NZSE:LIC) | NZ$1.04 | NZ$148.04M | ✅ 2 ⚠️ 5 View Analysis > |
Click here to see the full list of 937 stocks from our Asian Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
JBM (Healthcare) (SEHK:2161)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: JBM (Healthcare) Limited is an investment holding company involved in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products across Hong Kong, Macau, Mainland China, and international markets with a market cap of approximately HK$2.43 billion.
Operations: No specific revenue segments are reported for the company.
Market Cap: HK$2.43B
JBM (Healthcare) Limited, with a market cap of HK$2.43 billion, has demonstrated significant earnings growth, averaging 53.2% annually over the past five years, though recent growth slowed to 32%. The company's net profit margins improved from 22.7% to 26.6%, and its debt levels are well managed with a net debt to equity ratio of 13.8%. Despite having high-quality earnings and stable weekly volatility at 4%, its return on equity remains low at 19.8%. Recent financials show increased sales and net income for the half year ending September 2025, alongside strategic board appointments enhancing governance expertise in traditional Chinese medicine.
- Click to explore a detailed breakdown of our findings in JBM (Healthcare)'s financial health report.
- Evaluate JBM (Healthcare)'s prospects by accessing our earnings growth report.
Tong Tong AI Social Group (SEHK:628)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Tong Tong AI Social Group Limited, with a market cap of HK$1.27 billion, operates as an investment holding company providing commercial factoring and financial services in the People's Republic of China.
Operations: Tong Tong AI Social Group generates revenue primarily from its digital content ecosystem business, amounting to CN¥265.14 million.
Market Cap: HK$1.27B
Tong Tong AI Social Group Limited, with a market cap of HK$1.27 billion, has shown substantial revenue growth in its digital content ecosystem business, reaching CN¥202.68 million for the first half of 2025 compared to CN¥60.8 million a year ago. Despite this growth, net profit margins have decreased from 58.5% to 11.3%. The company maintains satisfactory debt levels with a net debt to equity ratio of just 0.5%, and its short-term assets comfortably cover both short- and long-term liabilities. However, negative operating cash flow indicates challenges in covering debt through cash generation, while return on equity remains low at 1.5%.
- Unlock comprehensive insights into our analysis of Tong Tong AI Social Group stock in this financial health report.
- Gain insights into Tong Tong AI Social Group's historical outcomes by reviewing our past performance report.
Biosino Bio-Technology and Science Incorporation (SEHK:8247)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Biosino Bio-Technology and Science Incorporation, along with its subsidiaries, focuses on the manufacturing, selling, and distribution of in-vitro diagnostic reagents in Mainland China and has a market cap of HK$260.47 million.
Operations: The company generates revenue primarily from its In-Vitro Diagnostic Reagent Products, amounting to CN¥225.06 million.
Market Cap: HK$260.47M
Biosino Bio-Technology and Science Incorporation, with a market cap of HK$260.47 million, faces challenges as its sales declined to CN¥95.82 million for the first half of 2025 from CN¥133.83 million the previous year, resulting in a net loss of CN¥17.98 million. Despite being unprofitable, it holds sufficient cash runway for over three years due to positive free cash flow growth and reduced debt levels over five years. However, its high net debt to equity ratio (58.3%) remains concerning alongside short-term liabilities exceeding short-term assets by CN¥26.8M, while share price volatility persists amid an inexperienced board and management team.
- Click here and access our complete financial health analysis report to understand the dynamics of Biosino Bio-Technology and Science Incorporation.
- Explore historical data to track Biosino Bio-Technology and Science Incorporation's performance over time in our past results report.
Taking Advantage
- Get an in-depth perspective on all 937 Asian Penny Stocks by using our screener here.
- Ready For A Different Approach? We've found 18 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if JBM (Healthcare) might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com